🔗 Share this article

Given that America proceeds with sweeping adjustments to its vaccine schedules, a particular individual has emerged in a surprising turn: Høeg, an American of Danish descent sports physician and public health researcher who initially gained attention by expressing skepticism about coronavirus shots throughout the global health crisis and has zeroed in on possible fatalities following Covid vaccination in her recent position at the US Food and Drug Administration (FDA).

Proposed Shifts to Childhood Vaccine Schedule

Public health authorities had intended to announce sweeping revisions to the childhood vaccination calendar earlier this month, aligning the US with Denmark’s national calendar, sources say – a major change that would place the US at odds with much of the world with insufficient data for benefit. The announcement has been pushed back until the next year.

Instead of the director of the vaccine center, Dr. Høeg is set to speak at the gathering. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the division this calendar year.

A Shift at the Regulatory Body

This interim role may indicate a strengthened alliance between the drug and vaccine branches as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it points to a renewed priority upon rolling back previously authorized immunizations at the FDA.

Høeg has frequently advocated for discontinuing certain pediatric vaccine recommendations in the US in order to be more similar to Denmark, a society with comprehensive healthcare and a number of inhabitants approximately the population of Wisconsin’s.

In her initial statements, she has kept her attention on vaccination policy – traditionally the responsibility of Prasad, director of the FDA’s CBER – as opposed to medication approval.

Concerns Over Background

Dr. Høeg has little discernible background in drug development, approval processes or leadership, which has been standard for past directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the commissioner and the vaccine center since earlier this year.

“It seems she lacks to have the requisite experience” for running the drug-regulation department, remarked Jonathan Howard. “She lacks experience running a scientific study. She is not versed in managing a sizeable institution. She is not an expert in drug approvals.”

Previous heads of CBER would “be deeply familiar with regulatory frameworks and the research of medication creation”, noted a former acting FDA commissioner. “Objectively, she doesn’t have the sort of resume that previous people who ran CBER have had.”

CDER has an vast portfolio at the agency, Woodcock pointed out.

“Everybody just focuses on the innovative therapies, but the generic drug division approves a multitude of generic drugs. There is also a biosimilars division, OTC medication office and other areas, and each of these must be looked after,” Dr. Woodcock noted. “The area you neglect, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a major leadership element to the role, which oversees in excess of 5,000 staff members. “It’s a huge administrative position, if you execute it properly,” she added.

Official Statement and Disputed Initiatives

When asked about concerns about Høeg’s credentials and whether this assignment indicates more teamwork among FDA leaders on immunizations, a spokesperson responded that the “inquiries stem from incorrect assumptions”.

“Her experience aligns with the functions of her job,” the spokesperson stated, citing the months Dr. Høeg spent guiding the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg assumes responsibility for the agency head's controversial fast-track approval initiative, a disputed rapid drug-approval program that apparently troubled her preceding directors. “How are these drugs being selected for this fast-track system? Who makes the decisions?” Dr. Howard asked. “There’s a lot of secrecy happening at the FDA right now.”

In general, he said, “the agency seems to be moving towards laxer regulations of pharmaceuticals, except for vaccines.”

Documented Past Work on Vaccines

Concerning immunizations, Høeg has a clearer, if concerning, past, critics said. She authored a research paper using unverified public submissions to assess the rate of heart inflammation following COVID-19 immunization. She advised the Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to imply Covid vaccines are pose a greater threat than they are.

Part of her “wish list” for the new government featured changing guidelines for novel immunizations and ending “unnecessary” vaccines, she remarked following the vote on a online show. At the FDA, Dr. Høeg has according to sources suggested barring young men from receiving Covid vaccinations.

“She’s an complete ideologue who starts off with her beliefs and tailors the evidence to retrofit the science in a highly deceptive, untruthful way,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined fellow skeptics, {like|